Abstract：【Objective】 To explore the efficacy monitoring and evaluation of tumor abnormal protein (TAP) in peripheral venous blood in patients with breast cancer. 【Methods】 A total of 80 cases of female breast cancer patients (the breast cancer group) admitted to the hospital and 68 healthy female volunteers (the control group) who underwent physical examination in our hospital at the same time period were selected for the study. The TAP levels between the breast cancer group and the control group were compared. According to the effect of chemotherapy, breast cancer patients were further divided into the effective group and the ineffective group. The clinical data of effective group and ineffective group were compared. Logistic regression analysis was used to analyze the influencing factors on the therapeutic efficacy of breast cancer patients. Receiver operating characteristic curve (ROC) was used to analyzed the evaluation value of tap in peripheral venous blood for the treatment effect of breast cancer patients. 【Results】 The TAP level of breast cancer group before treatment was higher than that of the control group (P<0.05). The total effective rate of chemotherapy for breast cancer patients was 48.75% (39/80). Compared to the effective group, patients in the ineffective group has higher proportion of clinical staging Ⅲ, poor differentiation, lymph node metastasis, estrogen receptor, progesterone receptor composition ratio and higher TAP level after treatment (P<0.05). The TAP decline rate in the ineffective group was lower than that in the effective group, the difference was statistically significant (P<0.05). Logistic regression analysis results showed that clinical stage, degree of differentiation, lymph node metastasis and TAP decline rate were the influencing factors in the treatment effect of breast cancer patients (P<0.05). ROC analysis showed that the optimal cut-off point for TAP to evaluate the treatment effect of breast cancer patients was 15.59%, with a sensitivity of 73.17%, a specificity of 82.05%, and an AUC value of 0.811. 【Conclusion】 TAP level in the peripheral venous blood is abnormally high in breast cancer patients, and the change of TAP levels before and after treatment is closely related to the treatment effect of breast cancer patients, so it can be used to monitor and evaluate the efficacy of breast cancer patients.
沈伟娟, 张溢. 外周静脉血肿瘤异常蛋白检测对乳腺癌患者的疗效监测及评估价值*[J]. 医学临床研究, 2021, 38(4): 508-511.
SHEN Wei-juan, ZHANG Yi. Monitoring and Evaluating Value of Tumor Abnormal Protein Detection in Peripheral Venous Blood of Patients with Breast Cancer. JOURNAL OF CLINICAL RESEARCH, 2021, 38(4): 508-511.
[1] CALDANA M,PELLINI F,LOMBARDI D,et al. Breast cancer and neoadjuvant chemotherapy: indications for and limits of breast-conserving surgery[J]. Ann Ital Chir,2018,89(11):392-397. [2] CHENG Y,CHEN Y,ZANG G,et al. Increased expression of TAP is predictive of poor prognosis in patients with non-small cell lung cancer [J].Cancer Manag Res,2020,12(8):1941-1946. [3] CHEN R,JIANG C,ZHU Q,et al. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3,and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer[J].Medicine,2020,99(29):21231. [4] SUN C,DENG F,MENG L,et al. Correlation between TAP detection and common digestive tract precancerous lesions [J].Oncol Lett,2018,15(2):1616-1620. [5] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J].中国癌症杂志,2017,9(1):695-759. [6] EISENHAUER E A,THERASSE P,BOGAERTS J,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J].Eur J Cancer,2009,45(2):1-247. [7] WAN C F,LIU X S,WANG L,et al. Quantitative contrast-enhanced ultrasound evaluation of pathological complete response in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy [J].Eur J Radiol,2018,103(11):118-123. [8] WU F T,WU W,LI X T,et al. Tumor abnormal protein level predicts disease response and progression of diffuse large b-cell lymphoma in the rituximab era [J].Clin Lab,2019,65(12):46-52. [9] 王勇,朱琳燕. 乳腺癌患者新辅助化疗前后血清TAP、CA125水平变化及与疗效的关系[J].河北医药,2019,41(9):132-134. [10] 杨云,黄元夕. 乳腺癌新辅助化疗疗效及其与生物标志物检测水平变化的相关性[J].现代肿瘤医学,2020,28(20):3546-3549. [11] Early Breast Cancer Trialists' Collaborative Group. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer:meta-analysis of individual patient data from ten randomised trials [J].Lancet Oncol,2018,19(1):27-39. [12] CHEN W X,YANG L G,CHENG L,et al. Tumor abnormal protein in the diagnosis of breast cancer in patients with a palpable mass [J].Ann Clin Lab Sci,2019,49(3):297-301.
2021, Vol. 38 
